Pharm-Olam's response to COVID-19 from CEO Rob Davie, PhD. Read Here

Request a Proposal  

Recruitment of Patients in a Phase III Systemic Lupus Erythematosus Study

During the planning of a Phase III Systemic Lupus Erythematosus (SLE) anti-B cell therapy, the Sponsor company called on Pharm-Olam to assist in the identification and enrollment of patients.

The purpose of the study was to determine the viability of a biological agent in treating SLE patients whose disease state was severe, aggressively advancing and poorly controlled. SLE is a notoriously difficult-to-diagnose autoimmune disorder with no known cure.

Study Details:

  • Phase III
  • Indication: Systemic Lupus Erythematosus (SLE)
  • Patients:209
  • Sites: 32
  • Countries: Belarus, Georgia, Guatemala, Mexico, Russia, and Sri Lanka

To see the full case study, click on the image to the right.